{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:36:15Z","timestamp":1793957775996,"version":"4.8.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008659","name":"European Committee for Treatment and Research in Multiple Sclerosis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ebiom.2025.105905","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T23:51:28Z","timestamp":1758153088000},"page":"105905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Positive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosis"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4541-8841","authenticated-orcid":false,"given":"Florian","family":"Deisenhammer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Hegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Arrambide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda L.","family":"Banwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3031-7549","authenticated-orcid":false,"given":"Tim","family":"Coetzee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilee","family":"Gnanapavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayrettin","family":"Tumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Willrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ebiom.2025.105905_bib1","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1468-1331.2009.02595.x","article-title":"EFNS guidelines on disease specific CSF investigations","volume":"16","author":"Deisenhammer","year":"2009","journal-title":"Eur J Neurol"},{"issue":"14","key":"10.1016\/j.ebiom.2025.105905_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cells12141911","article-title":"Liquid biopsy in neurological diseases","volume":"12","author":"Malhotra","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ebiom.2025.105905_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s42466-020-0051-z","article-title":"S1 guidelines \u201clumbar puncture and cerebrospinal fluid analysis\u201d (abridged and translated version)","volume":"2","author":"Tumani","year":"2020","journal-title":"Neurol Res Pract"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105905_bib4","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneur.62.6.865","article-title":"Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement","volume":"62","author":"Freedman","year":"2005","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105905_bib5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrneurol.2013.41","article-title":"The utility of cerebrospinal fluid analysis in patients with multiple sclerosis","volume":"9","author":"Stangel","year":"2013","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105905_bib6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105905_bib7","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001005","article-title":"Kappa-free light chains in CSF predict early multiple sclerosis disease activity","volume":"8","author":"Berek","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"Pt 7","key":"10.1016\/j.ebiom.2025.105905_bib8","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/brain\/awv105","article-title":"Defining high, medium and low impact prognostic factors for developing multiple sclerosis","volume":"138","author":"Tintore","year":"2015","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105905_bib9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ana.10441","article-title":"Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis","volume":"53","author":"Villar","year":"2003","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105905_bib10","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s00415-021-10436-6","article-title":"Functional neurological disorder and multiple sclerosis: a systematic review of misdiagnosis and clinical overlap","volume":"269","author":"Walzl","year":"2022","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105905_bib11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/WNL.0000000000006583","article-title":"Misdiagnosis of multiple sclerosis: impact of the 2017 McDonald criteria on clinical practice","volume":"92","author":"Solomon","year":"2019","journal-title":"Neurology"},{"issue":"1\u20132","key":"10.1016\/j.ebiom.2025.105905_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0165-5728(88)90041-0","article-title":"Free kappa and lambda light chain levels in the cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases","volume":"19","author":"Fagnart","year":"1988","journal-title":"J Neuroimmunol"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105905_bib13","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1212\/WNL.39.7.964","article-title":"Relative diagnostic value of cerebrospinal fluid kappa chains in MS: comparison with other immunoglobulin tests","volume":"39","author":"Rudick","year":"1989","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105905_bib14","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/13524585221134217","article-title":"Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: a consensus statement","volume":"29","author":"Hegen","year":"2023","journal-title":"Mult Scler"},{"issue":"15\u201316","key":"10.1016\/j.ebiom.2025.105905_bib15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10354-022-00912-7","article-title":"Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis-from diagnosis to prediction of disease activity","volume":"172","author":"Hegen","year":"2022","journal-title":"Wien Med Wochenschr"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105905_bib16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/jnnp.2003.010710","article-title":"Detection of oligoclonal free kappa chains in the absence of oligoclonal IgG in the CSF of patients with suspected multiple sclerosis","volume":"75","author":"Goffette","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105905_bib17","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1093\/brain\/awac220","article-title":"The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria","volume":"145","author":"Arrambide","year":"2022","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105905_bib18","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1177\/13524585211064121","article-title":"The contribute of cerebrospinal fluid free light-chain assay in the diagnosis of multiple sclerosis and other neurological diseases in an Italian multicenter study","volume":"28","author":"Bernardi","year":"2022","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105905_bib19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/ene.14121","article-title":"Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band-negative patients with suspected multiple sclerosis","volume":"27","author":"Ferraro","year":"2020","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105905_bib20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000235944","article-title":"The discovery of oligoclonal bands: a 50-year anniversary","volume":"62","author":"Holmoy","year":"2009","journal-title":"Eur Neurol"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105905_bib21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-0404.1990.tb00947.x","article-title":"Spleen versus CNS immunoglobulin G in multiple sclerosis: an isoelectric focusing study","volume":"81","author":"Mavra","year":"1990","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105905_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/jnnp.56.1.32","article-title":"The significance of serum oligoclonal bands in neurological diseases","volume":"56","author":"Zeman","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105905_bib23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1191\/1352458504ms988oa","article-title":"Oligoclonal bands in Devic's neuromyelitis optica and multiple sclerosis: differences in repeated cerebrospinal fluid examinations","volume":"10","author":"Bergamaschi","year":"2004","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105905_bib24","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1191\/1352458503ms947oa","article-title":"Is Devic's neuromyelitis optica a separate disease? A comparative study with multiple sclerosis","volume":"9","author":"de Seze","year":"2003","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105905_bib25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12974-020-01824-2","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: results from 163 lumbar punctures in 100 adult patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J Neuroinflammation"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105905_bib26","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1177\/1352458520981910","article-title":"Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability","volume":"27","author":"Capuano","year":"2021","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105905_bib27","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/10408363.2022.2039591","article-title":"Oligoclonal bands: clinical utility and interpretation cues","volume":"59","author":"Carta","year":"2022","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105905_bib28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0009-8981(01)00573-3","article-title":"Dynamics of brain-derived proteins in cerebrospinal fluid","volume":"310","author":"Reiber","year":"2001","journal-title":"Clin Chim Acta"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105905_bib29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-510X(94)90298-4","article-title":"Flow rate of cerebrospinal fluid (CSF)--a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases","volume":"122","author":"Reiber","year":"1994","journal-title":"J Neurol Sci"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105905_bib30","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1515\/cclm-2025-0007","article-title":"Impact of renal function impairment on kappa free light chain index","volume":"63","author":"Schmidauer","year":"2025","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105905_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/13524585221134213","article-title":"Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: a systematic review and meta-analysis","volume":"29","author":"Hegen","year":"2023","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105905_bib32","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1515\/cclm-2018-0400","article-title":"Cerebrospinal fluid free kappa light chains and kappa index perform equal to oligoclonal bands in the diagnosis of multiple sclerosis","volume":"57","author":"Christiansen","year":"2018","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105905_bib33","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000775","article-title":"Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS","volume":"7","author":"Duell","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ebiom.2025.105905_bib34","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cca.2018.12.006","article-title":"Intrathecal immunoglobulin synthesis: the potential value of an adjunct test","volume":"489","author":"Emersic","year":"2019","journal-title":"Clin Chim Acta"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105905_bib35","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1515\/cclm-2017-0901","article-title":"CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes","volume":"56","author":"Gurtner","year":"2018","journal-title":"Clin Chem Lab Med"},{"issue":"1\u20132","key":"10.1016\/j.ebiom.2025.105905_bib36","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jneuroim.2014.08.003","article-title":"High sensitivity and specificity of elevated cerebrospinal fluid kappa free light chains in suspected multiple sclerosis","volume":"276","author":"Hassan-Smith","year":"2014","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.ebiom.2025.105905_bib37","article-title":"Free light chains and intrathecal B cells activity in multiple sclerosis: a prospective study and meta-analysis","volume":"2016","author":"Passerini","year":"2016","journal-title":"Mult Scler Int"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105905_bib38","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.mayocp.2021.09.014","article-title":"CSF kappa free light chains: cutoff validation for diagnosing multiple sclerosis","volume":"97","author":"Saadeh","year":"2022","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105905_bib39","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00415-018-9106-2","article-title":"Validation of CSF free light chain in diagnosis and prognosis of multiple sclerosis and clinically isolated syndrome: prospective cohort study in Buenos Aires","volume":"266","author":"Saez","year":"2019","journal-title":"J Neurol"},{"key":"10.1016\/j.ebiom.2025.105905_bib40","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.clineuro.2018.09.031","article-title":"Relevance of KFLC quantification to differentiate clinically isolated syndrome from multiple sclerosis at clinical onset","volume":"174","author":"Vasilj","year":"2018","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105905_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77029-7","article-title":"Intrathecal kappa free light chains as markers for multiple sclerosis","volume":"10","author":"Vecchio","year":"2020","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105905_bib42","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/1352458515594044","article-title":"Validation of kappa free light chains as a diagnostic biomarker in multiple sclerosis and clinically isolated syndrome: a multicenter study","volume":"22","author":"Presslauer","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.ebiom.2025.105905_bib43","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cca.2019.07.027","article-title":"Diagnostic relevance of free light chains in cerebrospinal fluid - the hyperbolic reference range for reliable data interpretation in quotient diagrams","volume":"497","author":"Reiber","year":"2019","journal-title":"Clin Chim Acta"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105905_bib44","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1515\/cclm-2018-1300","article-title":"Free light chains in the cerebrospinal fluid. Comparison of different methods to determine intrathecal synthesis","volume":"57","author":"Hegen","year":"2019","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105905_bib45","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200156","article-title":"Kappa free light chain index predicts disease course in clinically and radiologically isolated syndromes","volume":"10","author":"Levraut","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105905_bib46","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1515\/cclm-2018-0028","article-title":"Cerebrospinal fluid free light chains as diagnostic biomarker in neuroborreliosis","volume":"56","author":"Hegen","year":"2018","journal-title":"Clin Chem Lab Med"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105905_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089945","article-title":"Kappa free light chains: diagnostic and prognostic relevance in MS and CIS","volume":"9","author":"Presslauer","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ebiom.2025.105905_bib48","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3389\/fimmu.2019.00641","article-title":"CSF free light chains as a marker of intrathecal immunoglobulin synthesis in multiple sclerosis: a blood-CSF barrier related evaluation in a large cohort","volume":"10","author":"Senel","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2025.105905_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1327947","article-title":"Diagnostic value of kappa free light chain index in patients with primary progressive multiple sclerosis - a multicentre study","volume":"14","author":"Hegen","year":"2023","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105905_bib50","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/ene.13667","article-title":"Kappa free light chains in cerebrospinal fluid to identify patients with oligoclonal bands","volume":"25","author":"Susse","year":"2018","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105905_bib51","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200386","article-title":"Diagnostic utility of kappa free light chain index in adults with inaugural optic neuritis","volume":"12","author":"Demortiere","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105905_bib52","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jamaneurol.2025.1481","article-title":"Prognostic factors for multiple sclerosis symptoms in radiologically isolated syndrome","volume":"82","author":"Fissolo","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ebiom.2025.105905_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577355","article-title":"Prognostic value of kappa free light chains determination in first-ever multiple sclerosis relapse","volume":"347","author":"Salavisa","year":"2020","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.ebiom.2025.105905_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104573","article-title":"Kappa free light chain and neurofilament light independently predict early multiple sclerosis disease activity-a cohort study","volume":"91","author":"Hegen","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ebiom.2025.105905_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105734","article-title":"Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients","volume":"88","author":"Tortosa-Carreres","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ebiom.2025.105905_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1223514","article-title":"Kappa free light chains index in multiple sclerosis very long-term prognosis","volume":"14","author":"Arroyo-Pereiro","year":"2023","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105905_bib57","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105905_bib58","article-title":"Neurofilament light chain levels in serum among a large mixed memory clinic cohort: confounders and diagnostic usefulness","volume":"15","author":"Simonsen","year":"2023","journal-title":"Alzheimers Dement (Amst)"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105905_bib59","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders - towards clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ebiom.2025.105905_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102807","article-title":"Clinical implications of serum neurofilament in newly diagnosed MS patients: a longitudinal multicentre cohort study","volume":"56","author":"Bittner","year":"2020","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105905_bib61","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebiom.2025.105905_bib62","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cca.2022.08.017","article-title":"Plasma neurofilament light chain (NfL) reference interval determination in an age-stratified cognitively unimpaired cohort","volume":"535","author":"Bornhorst","year":"2022","journal-title":"Clin Chim Acta"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105905_bib63","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/ana.26446","article-title":"Contributors to serum NfL levels in people without neurologic disease","volume":"92","author":"Fitzgerald","year":"2022","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105905_bib64","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcac174","article-title":"Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years","volume":"4","author":"Simren","year":"2022","journal-title":"Brain Commun"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105905_bib65","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/acn3.51704","article-title":"Associations of sNfL with clinico-radiological measures in a large MS population","volume":"10","author":"Sotirchos","year":"2023","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105905_bib66","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1002\/acn3.51676","article-title":"Age- and disease-specific reference values for neurofilament light presented in an online interactive support interface","volume":"9","author":"Vermunt","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"issue":"23","key":"10.1016\/j.ebiom.2025.105905_bib67","doi-asserted-by":"crossref","first-page":"e2448","DOI":"10.1212\/WNL.0000000000207957","article-title":"Agreement between published reference resources for neurofilament light chain levels in people with multiple sclerosis","volume":"101","author":"Sotirchos","year":"2023","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105905_bib68","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/eb-2012-100645","article-title":"Principles for high-quality, high-value testing","volume":"18","author":"Power","year":"2013","journal-title":"Evid Based Med"},{"key":"10.1016\/j.ebiom.2025.105905_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104008","article-title":"Oligoclonal bands, age 11-17 years, occipital lesion, and female sex differentiate pediatric multiple sclerosis from acute disseminated encephalomyelitis: a nationwide cohort study","volume":"66","author":"Boesen","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105905_bib70","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1515\/cclm-2017-0911","article-title":"Search for new biomarkers of pediatric multiple sclerosis: application of immunoglobulin free light chain analysis","volume":"56","author":"Ganelin-Cohen","year":"2018","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105905_bib71","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"issue":"11\u201312","key":"10.1016\/j.ebiom.2025.105905_bib72","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1177\/13524585241274034","article-title":"The kappa free light chains index is an accurate diagnostic biomarker for paediatric multiple sclerosis","volume":"30","author":"Sarthou","year":"2024","journal-title":"Mult Scler"},{"key":"10.1016\/j.ebiom.2025.105905_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104704","article-title":"High serum neurofilament levels are observed close to disease activity events in pediatric-onset MS and MOG antibody-associated diseases","volume":"74","author":"Ziaei","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105905_bib74","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(23)00284-3","article-title":"NfL is ready for translation into paediatrics","volume":"22","author":"Thebault","year":"2023","journal-title":"Lancet Neurol"},{"issue":"19","key":"10.1016\/j.ebiom.2025.105905_bib75","doi-asserted-by":"crossref","first-page":"e1873","DOI":"10.1212\/WNL.0000000000207791","article-title":"Pretreatment neurofilament light chain serum levels, early disease severity, and treatment response in pediatric multiple sclerosis","volume":"101","author":"Huppke","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.ebiom.2025.105905_bib76","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.clinbiochem.2023.04.006","article-title":"Variation in processes and reporting of cerebrospinal fluid oligoclonal banding and associated tests and calculated indices across Canadian clinical laboratories","volume":"116","author":"Higgins","year":"2023","journal-title":"Clin Biochem"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105905_bib77","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200270","article-title":"Association of complement factors with disability progression in primary progressive multiple sclerosis","volume":"11","author":"Lunemann","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105905_bib78","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae209","article-title":"Potential biomarkers for multiple sclerosis stage from targeted proteomics and microRNA sequencing","volume":"6","author":"Tan","year":"2024","journal-title":"Brain Commun"},{"issue":"13","key":"10.1016\/j.ebiom.2025.105905_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25137399","article-title":"Cytokine profiling in cerebrospinal fluid of patients with newly diagnosed relapsing-remitting multiple sclerosis (RRMS): associations between inflammatory biomarkers and disease activity","volume":"25","author":"Gebka-Kepinska","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105905_bib80","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200230","article-title":"CD138 as a specific CSF biomarker of multiple sclerosis","volume":"11","author":"Hinsinger","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105905_bib81","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200265","article-title":"Association of levels of CSF osteopontin with cortical atrophy and disability in early multiple sclerosis","volume":"11","author":"Marastoni","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105905_bib82","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1007\/s00415-024-12587-8","article-title":"Cerebrospinal fluid neurofilament light chain in acute optic neuritis and its predictive ability of multiple sclerosis","volume":"271","author":"Passali","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.ebiom.2025.105905_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.104970","article-title":"Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management","volume":"101","author":"Freedman","year":"2024","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105905_bib84","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/jalm\/jfaa093","article-title":"Free light chain assay drift: potential for misdiagnosis?","volume":"5","author":"Murray","year":"2020","journal-title":"J Appl Lab Med"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105905_bib85","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/jalm.2019.029330","article-title":"Serum free light chain assay: shift toward a higher kappa\/lambda ratio","volume":"5","author":"Rindlisbacher","year":"2020","journal-title":"J Appl Lab Med"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105905_bib86","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jalm\/jfad027","article-title":"Kappa free light chain drift prompts the need for a new upper limit of normal free light chain ratio to avoid an epidemic of kappa light chain monoclonal gammopathy of undermined significance","volume":"8","author":"Rozenova","year":"2023","journal-title":"J Appl Lab Med"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105905_bib87","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1515\/cclm-2019-0533","article-title":"Method comparison of four clinically available assays for serum free light chain analysis","volume":"58","author":"Fleming","year":"2019","journal-title":"Clin Chem Lab Med"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105905_bib88","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/ajcp\/aqx037","article-title":"Performance evaluation of serum free light chain analysis: nephelometry vs turbidimetry, monoclonal vs polyclonal reagents","volume":"147","author":"Messiaen","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ebiom.2025.105905_bib89","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.clinbiochem.2018.06.003","article-title":"Reference intervals and diagnostic ranges for serum free kappa and free lambda immunoglobulin light chains vary by instrument platform: implications for classification of patient results in a multi-center study","volume":"58","author":"Cotten","year":"2018","journal-title":"Clin Biochem"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105905_bib90","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1515\/cclm-2023-0473","article-title":"A universal reference interval for serum immunoglobulins free light chains may be outdated","volume":"61","author":"Fink","year":"2023","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105905_bib91","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ebiom.2025.105905_bib92","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cca.2020.12.030","article-title":"FLC polymerization: another hurdle towards standardization of FLC measurements","volume":"515","author":"Kaplan","year":"2021","journal-title":"Clin Chim Acta"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105905_bib93","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1515\/cclm-2013-0864","article-title":"N Latex FLC serum free light-chain assays in patients with renal impairment","volume":"52","author":"Jacobs","year":"2014","journal-title":"Clin Chem Lab Med"},{"issue":"12","key":"10.1016\/j.ebiom.2025.105905_bib94","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.clml.2016.08.012","article-title":"Evaluation of the impact of renal failure on correlation and concordance between 2 free light chain assays","volume":"16","author":"Moreau","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105905_bib95","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ekir.2020.01.019","article-title":"Comparison of 2 serum-free light-chain assays in CKD patients","volume":"5","author":"Sprangers","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105905_bib96","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1515\/cclm-2023-0912","article-title":"Clinical specificity of two assays for immunoglobulin kappa and lambda free light chains","volume":"62","author":"Farnsworth","year":"2024","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105905_bib97","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1515\/cclm-2018-1369","article-title":"Prognostic value of involved\/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients","volume":"57","author":"Henriot","year":"2019","journal-title":"Clin Chem Lab Med"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105905_bib98","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1515\/cclm-2016-1024","article-title":"Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays","volume":"55","author":"Palladini","year":"2017","journal-title":"Clin Chem Lab Med"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105905_bib99","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41408-022-00722-5","article-title":"Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma","volume":"12","author":"Willrich","year":"2022","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105905_bib100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166556","article-title":"Assessment of intrathecal free light chain synthesis: comparison of different quantitative methods with the detection of oligoclonal free light chains by isoelectric focusing and affinity-mediated immunoblotting","volume":"11","author":"Zeman","year":"2016","journal-title":"PLoS One"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425003494?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425003494?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T17:41:06Z","timestamp":1772905266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425003494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":100,"alternative-id":["S2352396425003494"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105905","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Positive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105905"}}